James W. Jakub
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James W. Jakub.
Journal of Clinical Oncology | 2008
David F. McDermott; Jeffrey A. Sosman; Rene Gonzalez; F. Stephen Hodi; Gerald P. Linette; Jon Richards; James W. Jakub; Muralidhar Beeram; Stefano Tarantolo; Sanjiv S. Agarwala; Gary Frenette; Igor Puzanov; Lee D. Cranmer; Karl D. Lewis; John M. Kirkwood; J. Michael White; Chenghua Xia; Kiran Patel; Evan M. Hersh
PURPOSE This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma. PATIENTS AND METHODS This randomized, double-blind, placebo-controlled, multicenter study enrolled chemotherapy-naive patients with stage III (unresectable) or IV melanoma. A total of 101 patients received placebo plus dacarbazine (n = 50) or sorafenib plus dacarbazine (n = 51). On day 1 of a 21-day cycle, patients received intravenous dacarbazine 1,000 mg/m(2) for a maximum of 16 cycles. Oral sorafenib 400 mg or placebo was administered twice a day continuously. The primary end point was progression-free survival (PFS) by independent assessment. Secondary and tertiary end points included time to progression (TTP), response rate, and overall survival (OS). RESULTS Median PFS in the sorafenib plus dacarbazine arm was 21.1 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (hazard ratio [HR], 0.665; P = .068). There were statistically significant improvements in PFS rates at 6 and 9 months, and in TTP (median, 21.1 v 11.7 weeks; HR, 0.619) in favor of the sorafenib plus dacarbazine arm. No difference in OS was observed (median, 51.3 v 45.6 weeks in the placebo plus dacarbazine and sorafenib plus dacarbazine arms, respectively; HR, 1.022). The regimen was well tolerated and had a manageable toxicity profile. CONCLUSION Sorafenib plus dacarbazine was well tolerated in patients with advanced melanoma and yielded an encouraging improvement in PFS. Based on these findings, additional studies with the combination are warranted in this patient population.
Cancer and Metastasis Reviews | 2006
Stanley P. L. Leong; Blake Cady; David M. Jablons; Julio Garcia-Aguilar; Douglas S. Reintgen; James W. Jakub; Solange Pendas; L. Duhaime; R. Cassell; Mary Gardner; Rosemary Giuliano; V. Archie; D. Calvin; L. Mensha; Steven C. Shivers; Charles E. Cox; Jochen A. Werner; Yuko Kitagawa; Masaki Kitajima
In human solid cancer, lymph node status is the most important indicator for clinical outcome. Recent developments in the sentinel lymph node concept and technology have resulted in a more precise way of examining micrometastasis in the sentinel lymph node and the role of lymphovascular system in the facilitation of cancer metastasis.Different patens of metastasis are described with respect to different types of solid cancer. Expect perhaps for papillary carcinoma and sarcoma, the overwhelming evidence is that solid cancer progresses in an orderly progression from the primary site to the regional lymph node or the sentinel lymph node in the majority of cases with subsequent dissemination to the systemic sites. The basic mechanisms of cancer metastasis through the lymphovascular system form the basis of rational therapy against cancer. Beyond the clinical patterns of metastasis, it is imperative to understand the biology of metastasis and to characterize patterns of metastasis perhaps due to heterogeneous clones based on their molecular signatures.
Journal of The American Academy of Dermatology | 2013
Tina I. Tarantola; Laura A. Vallow; Michele Y. Halyard; Roger H. Weenig; Karen E. Warschaw; Travis E. Grotz; James W. Jakub; Randall K. Roenigk; Jerry D. Brewer; Amy L. Weaver; Clark C. Otley
BACKGROUND Knowledge regarding behavior of and prognostic factors for Merkel cell carcinoma (MCC) is limited. OBJECTIVE We sought to further understand the characteristics, behavior, prognostic factors, and optimal treatment of MCC. METHODS A multicenter, retrospective, consecutive study of patients with known primary MCC was completed. Overall survival and survival free of locoregional recurrence were calculated and statistical analysis of characteristics and outcomes was performed. RESULTS Among the 240 patients, the mean age at diagnosis was 70.1 years, 168 (70.0%) were male, and the majority was Caucasian. The most common location was head and neck (111, 46.3%). Immunosuppressed patients had significantly worse survival, with an overall 3-year survival of 43.4% compared with 68.1% in immunocompetent patients. In our study, patients with stage II disease had improved overall survival versus those with stage I disease, in a statistically significant manner. Patients with stage III disease had significantly worse survival compared with stage I and with stage II. Primary tumor size did not predict nodal involvement. CONCLUSION The data presented represent one of the largest series of primary MCC in the literature and confirm that MCC of all sizes has metastatic potential, supporting sentinel lymph node biopsy for all primary MCC. Because of the unpredictable natural history of MCC, we recommend individualization of care based on the details of each patients tumor and clinical presentation.
The American Journal of Surgical Pathology | 2004
Nils M. Diaz; Charles E. Cox; Mark D. Ebert; John D. Clark; Vesna Vrcel; Nicholas Stowell; Anu Sharma; James W. Jakub; Alan Cantor; Barbara A. Centeno; Elisabeth L. Dupont; Carlos A. Muro-Cacho; Santo V. Nicosia
The evaluation of sentinel lymph nodes (SLNs) for the presence of malignant epithelial cells is essential to the staging of breast cancer patients. Recently, increased attention has focused on the possibility that epithelial cells may reach SLNs by benign mechanical means, rather than by metastasis. The purpose of this study was to test the hypothesis that pre-SLN biopsy breast massage, which we currently use to facilitate the localization of SLNs, might represent a mode of benign mechanical transport. We studied 56 patients with invasive and/or in situ ductal carcinoma and axillary SLNs with only epithelial cells and/or cell clusters (≤0.2 mm in diameter and not associated with features of established metastases) detected predominantly in subcapsular sinuses of SLNs on hematoxylin and eosin- and/or anti-cytokeratin-stained sections. No patient had an SLN involved by either micro- or macro-metastatic carcinoma. Epithelial cells and cell clusters, ≤0.2 mm in size and without features of established metastases, occurred more frequently in the SLNs of patients who underwent pre-SLN biopsy breast massage (P < 0.001, χ2 test). The latter finding supports the hypothesis that pre-SLN biopsy breast massage is a mode of benign mechanical transport of epithelial cells to SLNs.
Journal of Surgical Oncology | 2010
Jeffrey S. Scow; Carol Reynolds; Amy C. Degnim; Ivy A. Petersen; James W. Jakub; Judy C. Boughey
Angiosarcoma of the breast can be divided into primary and secondary. The objective was to determine clinicopathologic factors associated with breast angiosarcoma and to compare primary versus secondary angiosarcoma.
American Journal of Surgery | 2002
James W. Jakub; Nils M. Diaz; Mark D. Ebert; Alan Cantor; Douglas S. Reintgen; Elisabeth L. Dupont; Alan R. Shons; Charles E. Cox
OBJECTIVE To document the incidence of metastatic disease in complete axillary lymph node dissections (CALND) of patients with invasive carcinoma after a sentinel lymph node (SLN) biopsy, positive only by immunohistochemical staining for cytokeratin (CK-IHC). METHODS Sections of all SLNs, negative by routine histology, were immunostained and examined for cytokeratin positive cells. Sections of lymph nodes from CALND specimens were interpreted using routine hematoxylin and eosin (H&E) staining. RESULTS A total of 409 patients (29.6%) had metastatic disease in at least one sentinel lymph node on H&E examination. Of 971 H&E negative patients, 78 (8.0%) were positive only by CK-IHC. Sixty-two of the CK-IHC positive only patients underwent CALND. Nine of these 62 patients (14.5%) had metastases identified in the CALND specimen. CONCLUSIONS Because 14.5% of patients with invasive breast cancer and SLNs positive only by CK-IHC were found to have H&E positive lymph nodes on CALND, we conclude first, that CK-IHC should be used to evaluate SLNs, and second, that CALND should be considered when SLNs are positive by CK-IHC only. This approach will result in an absolute reduction of the false negative rate (absolute false negative rate reduced by 2.6% in our series).
Annals of Surgical Oncology | 2011
John B. Osborn; Gary L. Keeney; James W. Jakub; Amy C. Degnim; Judy C. Boughey
BackgroundNegative margins are associated with decreased local recurrence after lumpectomy for breast cancer. A 2nd operation for re-excision of positive margins is required with rates varying from 15 to 50%. At our institution we routinely use frozen-section analysis of all margins to minimize rates of 2nd operations. The aim of this study was to evaluate the cost/benefit of routine frozen-section analysis.MethodsA decision tree was built to compare 2 strategies: (A) lumpectomy without frozen section and a 2nd operation for positive margin(s) versus (B) lumpectomy with intraoperative frozen-section analysis and a 2nd operation for positive margin(s). For strategy A the rate of positive margins and reoperation were varied from 15 to 50%. For strategy B, a 2nd operation rate of 3% was used. Review of our institutional experience demonstrates an intraoperative re-excision of at least 1 margin in 57% of cases performed with frozen-section support.ResultsThe cost to provider (i.e., institution) per patient resected to negative margins for strategy A ranged from
Plastic and Reconstructive Surgery | 2004
James W. Jakub; Mark D. Ebert; Alan Cantor; Mary Gardner; Douglas S. Reintgen; Elisabeth L. Dupont; Charles E. Cox; Alan R. Shons
4835 to
Surgery | 2014
Judy C. Boughey; Tina J. Hieken; James W. Jakub; Amy C. Degnim; Clive S. Grant; David R. Farley; Kristine M. Thomsen; John B. Osborn; Gary L. Keeney; Elizabeth B. Habermann
6306. Average weighted cost of strategy B was
Annals of Surgical Oncology | 2011
Carol Reynolds; Jennifer A. Davidson; Noralane M. Lindor; Katrina N. Glazebrook; James W. Jakub; Amy C. Degnim; Nicole P. Sandhu; Molly F. Walsh; Lynn C. Hartmann; Judy C. Boughey
5708. Strategy B was less expensive when the reoperation rate was above 36%. The cost to payor (i.e., Medicare) for strategy A ranged from